Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT04955041 |
Other study ID # |
M2020317 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 2010 |
Est. completion date |
June 2022 |
Study information
Verified date |
July 2020 |
Source |
Peking University Third Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Utilization of T2* MRI in predicting prognosis in patients with cervical spondylotic
myelopathy (CSM)
Description:
Cervical spondylotic myelopathy (CSM), an age-related degenerative disease that is common
worldwide, is mainly caused by compression of the spinal cord and may possibly lead to
disability. Surgery to reduce direct compression of the spinal cord might alleviate disease
progression; due to individual differences, some patients do not benefit from surgery.
Prognostic prediction is important because it affects subsequent treatment decision making.
Currently, prognosis is generally based on magnetic resonance imaging (MRI) with a detailed
macrostructural evaluation of the spinal cord. Unfortunately, the use of conventional MRI
indicators (e.g., increased intensity signal [ISI]) to predict CSM outcomes has been
controversial because of their subjectivity or the insufficient information contained
therein.
A new biomarker, T2* MRI gray matter to white matter signal intensity ratio (GM/WM), is
associated with demyelination and gliosis. Previous studies have shown that patients with CSM
can have T2* MRI WM / GM changes at the early stage of disease, and the WM / GM value is
increased, which is significantly higher than that of normal people, and is related to the
spinal cord function score. However, the correlation between this index and long-term
prognosis remains to be studied.